Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology

Inclusion Criteria:

1. Patient less than or equal to 21 years of age at inclusion.

2. Patient for whom a central catheter is planned to be inserted*, excluding anon-tunneled femoral or cervical external catheter or a peripherally insertedcentral catheter (as PICC line). *1st catheter placement or placement following arelapse (this placement must take place at least one month after previous catheterremoval).

3. Patient treated for a cancer.

4. Patient with regular follow-up in the inclusion center.

5. Informed consent signed by the patient if adult or by legal representatives ifminor.

6. Patient benefiting from a social security coverage.

7. Time between the date of catheter placement and the planned date for the firstsolution lock injection less than 6 weeks.

Exclusion Criteria:

1. Patient with retinoblastoma.

2. Allografted patient.

3. Patient with a life expectancy of less than 6 months.

4. Patient refusing to participate in the protocol.

5. Patient already receiving a central venous catheter-related infection preventionlock (ILCVC).

6. Patient with known allergy to citrate or (cyclo)-Taurolidine.

7. Patient taking other drugs with a known contraindication with citrate or (cyclo)-Taurolidine.

8. Patient with an external femoral catheter.

9. Patient with a PICCLINE-type peripheral venous inserted central catheter.

10. Patient unable to submit to the medical follow-up of the trial for geographical,social or psychological reasons.

11. Patient under guardianship and curatorship.